Science AI Journal
Medicine · Research topic

Open research questions in Esophageal Cancer Research and Treatment

39 unresolved questions extracted from the limitations and future-work sections of 218 Esophageal Cancer Research and Treatment papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Future research should investigate the optimal implementation of glycemic control strategies for ESCC patients with T2DM, as well as the role and the specific mechanisms of medications such as metformin in enhancing survival outcomes, thereby provid- ing better guidance for clinical practice.

    Type 2 diabetes mellitus confers unfavorable short- and long-term outcomes in patients undergoing esophagectomy · 2026 · DOI

  • Among these, the rs12778366 polymorphism has been studied in various cancers; how- ever, to date, limited information is available regarding its role in esophageal cancer. Therefore, larger studies incorporating detailed gene–environment interaction analyses and func- tional validation are warranted.

    Association of SIRT1 rs12778366 (T > C) polymorphism with reduced esophageal cancer risk: a case–control study from North India” · 2026 · DOI

  • Future research should focus on combining SIB with modern systemic therapies and refining boost volume definition using advanced imaging to enhance outcomes and support personalized treatment approaches.

    Real-World Outcomes of SIB-Based Concurrent Chemoradiation Therapy for Upper-Third Esophageal Cancer: A Single-Center Retrospective Study in Vietnam. · 2026 · DOI

  • Tissue Systems Pathology-9 Test (TSP-9; TissueCypher™) is a molecular assay identifying patients at higher progression risk, but data from Latin America are lacking.

    Early Implementation of TSP-9 for Risk Stratification in Barrett’s Esophagus: Influence on Management Decisions in Latin America · 2026 · DOI

  • However, STER is unsuitable for complex esophageal lesions that are large and/or located in the cervical esophagus, because there is insufficient space to create a submucosal tunnel and to allow effective endoscopic manipulation.

    Exposed endoscopic full-thickness resection <i>vs</i> thoracoscopic surgery for complex esophageal subepithelial lesions arising from the muscularis propria · 2026 · DOI

  • This study has several limitations. It was a retrospective single-health-board audit with a small sample size and an active-treatment cohort, limiting generalizability to all patients with UGI cancer. Multiple variables were incompletely or inconsistently documented, including ECOG performance status, comorbidity burden, overall clinical stage grouping, treatment intent, dose reduction, surgical procedure type, structured 2026 Lohani et al. Cureus 18(6): e111600. DOI 10.7759/cureus.111600 8 of 10 complication grading, median follow-up, event timing, and censoring status. Patient-level overall postoperative complication incidence could not be reliably calculated. Kaplan-Meier analysis, median PFS, median follow-up, confidence intervals, and inferential statistical testing were not performed. These limitations mean that findings should be regarded as descriptive.

    Upper Gastrointestinal Cancer Audit: A Retrospective Analysis of Patient Outcomes in North Wales · 2026 · DOI

  • Future work should focus on prospective data collection using a predefined audit proforma, standardized definitions of postoperative complications, Clavien-Dindo and CTCAE grading, accurate chemotherapy completion and dose-modification data, structured follow-up dates, recurrence/progression dates, and time-to-event analysis. Multicenter collaboration may improve sample size and generalizability. Prospective evaluation would also allow more rigorous assessment of perioperative optimization, prehabilitation, enhanced recovery pathways, and MDT processes.

    Upper Gastrointestinal Cancer Audit: A Retrospective Analysis of Patient Outcomes in North Wales · 2026 · DOI

  • Additional pathways to explore the role of CLE as a clinical biomarker in patients with DGBIs are available and will need to be studied in future research. CLE has also been studied for evaluation of acute mucosal reactions after intraduodenal endoscopic food application, but studies report mixed results regarding the ability of this approach to predict clini- cal improvement from CLE-guided dietary restriction.

    The Role of Confocal Laser Endomicroscopy in Disorders of Gut–Brain Interaction: A Narrative Review · 2026 · DOI

  • There are numerous limitations of the currently available literature evaluating the application of CLE in patients with DGBIs. First, the number of available studies is small overall, most studies are from single centers, and many have relatively small sample sizes. Second, studies commonly include not-well-defined DGBI pa- DOI: 10.14218/JTG.2026.00009 | Volume 00 Issue 00, Month Year 5 J Transl Gastroenterol Nojkov, B.: CLE in DGBIs tient populations, analyze different outcomes, and are frequently uncontrolled. Technically, there is heterogeneity in applied proto- cols among many of the studies, including location of CLE evalu- ation in the gastrointestinal tract and interpretation criteria used to analyze the gastrointestinal epithelium. Furthermore, while the reproducibility of qualitative CLE image analysis for acute food- induced reactions has been evaluated in a single study,44 the re- producibility of a well-defined CLE criteria set for in-depth quan- titative evaluation of barrier integrity/microscopic inflammation needs further evaluation.

    The Role of Confocal Laser Endomicroscopy in Disorders of Gut–Brain Interaction: A Narrative Review · 2026 · DOI

  • CLE is an established, globally available technology that can be an adjunct to standard gastrointestinal endoscopy to enable micro- scopic evaluation of the gastrointestinal surface epithelium in real time.27,30 Prior research in animal models and patients with IBD found CLE capable of identifying gastrointestinal mucosal abnor- malities that are reflective of epithelial barrier impairment and/or “low-grade” immune activation.23,24,49–53 These features enable exciting opportunities to apply CLE in patients with DGBIs, as these mechanisms have been found to be central in the pathogen- esis of multiple DGBIs.11,15–21 The currently available literature implementing CLE in patients with DGBIs is scarce and limited but is evolving. Preliminary con- trolled studies in both patients with IBS and FD,31,32,38 utilizing a standardized approach with in-depth analysis of CLE images, found evidence of increased epithelial gap density (increased rate of epithelial cell extrusion that has been associated with inflam- matory conditions) in the small intestine of affected patients com- pared with asymptomatic controls. These data need further valida- tion in larger, multicenter studies with well-defined DGBI patient populations and CLE procedural/analysis protocols. Parallel as- sessment of biopsied mucosa obtained from areas corresponding to CLE imaging will also enhance the strength of the evidence connecting CLE findings with proposed physiologic functions. Furthermore, standardization and validation of additional quanti- tative CLE analysis parameters may allow development of scor- ing systems with “diagnostic” thresholds specific for patients with individual DGBIs. The role of CLE in the clinical management of patients with DGBIs has not yet been established. A significant proportion of completed work dedicated to CLE in DGBIs involves the con- cept of endoscopic intraduodenal food constituent application followed by immediate CLE assessment for acute post-exposure mucosal alterations and subsequent dietary restriction based on these results.38–40,42–47 While initial preliminary studies and subse- quent38,39 uncontrolled observational reports found clinical bene- fits from this approach in a substantial proportion (>50%) of tested patients,45,47 two recent double-blind controlled studies were not able to replicate these findings.40,42 Furthermore, the pathophysi- ology explaining observed CLE abnormalities immediately after luminal food application remains unclear, and certain technical and interpretation questions related to the proposed CLE protocol require further study.43 An alternative approach for clinical use of CLE in DGBIs is to utilize its ability to detect inherent microscopic mucosal ab- normalities (alterations in epithelial barrier structure/function, “low-grade” immune activation) in subsets of patients and evalu- ate whether these findings are predictive of clinical response to selected therapies that are known to modulate these mechanisms (e.g., dietary interventions, microbiota manipulation). Such an ap- proach has not been tested in clinical studies but may allow an op- portunity to develop CLE as a clinically applicable biomarker and potentially provide a pathway toward personalized care in patients with DGBIs.

    The Role of Confocal Laser Endomicroscopy in Disorders of Gut–Brain Interaction: A Narrative Review · 2026 · DOI

  • Background: The extent and targets of lymphadenectomy for esophageal squamous cell carcinoma (ESCC) remain debated, and clinically intuitive visualizations of station-specific metastasis may facilitate surgical decision-making.

    Postoperative Outcomes, Lymph Node Metastasis Patterns, Prognostic Factors, and Multivariable Logistic Regression–Based Postoperative Station-Level Nodal Risk Prediction in ESCC Patients Undergoing Minimally Invasive McKeown Esophagectomy · 2026 · DOI

  • In contemporary practice, CT is usually the first staging examination, whereas EUS-FNA and PET/CT may be limited by access, scheduling, cost, or local expertise (1–5).

    Self-supervised 3D deep learning on preoperative contrast-enhanced computed tomography for predicting high pathologic nodal burden in esophageal squamous cell carcinoma: temporal and external multicohort validation · 2026 · DOI

  • strength and adherence rates To examine the relationship between guideline recommendation strength and real-world practice, we analyzed adherence rates for selected CQs from the 5th Edition of the Japanese Esophageal Cancer Practice Guidelines (Table 1 and Fig. 1). CQs representing clinical practices generally available across institutions were included in this analysis. CQs related to highly specialized treatments that are not widely available (e.g., PDT, proton-beam therapy, and salvage surgery) were excluded. In addition, CQs for which recommendation strength could not be clearly determined in the guideline were not included. In the 5th Edition of the guidelines, four CQs were categorized as strong recommendations. The adherence rates for these practices were consistently high across institutions, ranging from 87.9 to 94.7%. In contrast, CQs categorized as weak recommendations showed a wider range of adherence rates, from 66.3 to 92.1%. CQs jointly developed in collaboration with the Japanese Gastric Cancer Treatment Guidelines were categorized as weak recommendations; however, adherence rates for these practices ranged from 92.1 to 98.4%. Table 1 Relationship between guideline recommendations and adherence rates in the nationwide QI survey CQ CQ3: Diagnostic modalities to distinguish T1b-SM1 or shallower vs.

    Nationwide quality indicator survey on the current practice of esophageal cancer management in Japan: report from the guideline committee for the 6th edition of the Japanese Esophageal Cancer Practice Guidelines · 2026 · DOI

  • A further limitation of this study was that we did not identify any significant predictors of ETS despite evalua- tion of several clinical and laboratory parameters, including PD-L1 expression and systemic inflammatory and nutri- tional markers. Future studies are needed to confirm our findings and examine the association of ETS with long-term survival for esophageal cancer patients who received ICIs.

    Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study · 2026 · DOI

  • 2023;15:765. https://doi.org/10.3390/cancers15030765. 12. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for J Clinicians. 2021;71:209–49.

    Identification of replication factor C subunit 4 as a potential therapeutic target in esophageal squamous cell carcinoma based on bioinformatic analysis and machine learning · 2026 · DOI

  • A planned multi-center prospective study will evaluate immunotherapeutic agent differences in esophageal adenocarcinoma, but specific endpoints, patient selection criteria, and statistical power calculations for detecting survival differences between pembrolizumab and domestic agents in adenocarcinoma have not been detailed.

    Effectiveness comparison of pembrolizumab versus other immune checkpoint inhibitors in neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma · 2026 · DOI

  • A detailed comparative analysis of immune-related adverse events and side effect profiles between domestic and imported checkpoint inhibitors could not be completed due to cross-departmental privacy policies; future studies must systematically compare toxicity profiles and adverse event incidence between pembrolizumab and domestic immunotherapeutic agents in ESCC neoadjuvant chemoimmunotherapy.

    Effectiveness comparison of pembrolizumab versus other immune checkpoint inhibitors in neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma · 2026 · DOI

  • The pembrolizumab sample size was relatively small in this study; future multi-center prospective research must increase the sample size of pembrolizumab cohorts and involve more medical centers to capture potential prognostic differences between pembrolizumab and domestic checkpoint inhibitors in neoadjuvant chemoimmunotherapy for ESCC.

    Effectiveness comparison of pembrolizumab versus other immune checkpoint inhibitors in neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma · 2026 · DOI

  • The authors acknowledge potential heterogeneity among domestic immune checkpoint inhibitors but did not conduct individual head-to-head comparisons between specific domestic agents; future research must evaluate differential treatment outcomes between individual domestic immunotherapeutic agents in ESCC neoadjuvant settings.

    Effectiveness comparison of pembrolizumab versus other immune checkpoint inhibitors in neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma · 2026 · DOI

  • Future large-scale studies, including func- tional assays, are warranted to confirm this association and to elucidate the underlying molecular mechanisms.

    Association of SIRT1 rs12778366 (T > C) polymorphism with reduced esophageal cancer risk: a case–control study from North India” · 2026 · DOI

  • The HUGO RAS system represents a novel modular platform with limited data in esophageal surgery.

    First Reported Ivor Lewis Esophagectomy Using the HUGO RAS System in a High-Volume Center: A Technical Feasibility Report and Configurational Setup · 2026 · DOI

  • it should be noted that the GBD risk factor attri- bution is limited to a predefined set of exposures including tobacco, alcohol and diet.

    The global burden of oesophageal cancer from 1990 to 2023 and projections to 2040: a comprehensive analysis of the Global Burden of Disease Study 2023 · 2026 · DOI

  • The clinical benefit of staple-line oversewing in TMC anastomosis has not been fully clarified.

    Clinical Impact of Staple-Line Oversewing in Totally Mechanical Collard Cervical Anastomosis for Esophageal Cancer · 2026 · DOI

  • Although, both surgeries are available for Siewert type II GEJ cancer, it remains unknown which one is superior.

    Surgical Treatment of Siewert II Gastroesophagel Junction Adenocarcinoma: Esophagectomy or Gastrectomy? Review · 2022 · DOI

Most-cited papers in Esophageal Cancer Research and Treatment

Most recent work

Find a gap in your own Esophageal Cancer Research and Treatment sub-topic

This page shows what the Esophageal Cancer Research and Treatment literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
989 open questions
Artificial Intelligence in Healthcare and Education
607 open questions
Attention Deficit Hyperactivity Disorder
448 open questions
Physical Activity and Health
436 open questions
Smoking Behavior and Cessation
402 open questions
Innovations in Medical Education
364 open questions
Dementia and Cognitive Impairment Research
363 open questions
HIV/AIDS Research and Interventions
342 open questions
39 open questions have been extracted from the limitations and future-work passages of 218 Esophageal Cancer Research and Treatment papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.